Entera Bio Valuation
| ENTX Stock | USD 1.60 0.02 1.27% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Entera Bio shows a prevailing Real Value of $1.54 per share. The current price of the firm is $1.6. Our model computes the value of Entera Bio from reviewing the firm fundamentals such as Shares Owned By Insiders of 24.55 %, operating margin of (87.29) %, and Shares Outstanding of 45.86 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Entera Bio's price fluctuation is dangerous at this time. Calculation of the real value of Entera Bio is based on 3 months time horizon. Increasing Entera Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Entera Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Entera Stock. However, Entera Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.6 | Real 1.54 | Hype 1.6 | Naive 1.73 |
The intrinsic value of Entera Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Entera Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Entera Bio helps investors to forecast how Entera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Entera Bio more accurately as focusing exclusively on Entera Bio's fundamentals will not take into account other important factors: About Entera Bio Valuation
Our relative valuation model uses a comparative analysis of Entera Bio. We calculate exposure to Entera Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Entera Bio's related companies.Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.